Tuesday, March 17, 2026

Taurus Network Goes Live With 35 Institutions for Cross-Border Trades

Swiss fintech firm Taurus launches Taurus-NETWORK, a platform for digital asset collaboration, enhancing control and reducing risks for institutions.

North Korean Leader Links 80th Liberation Anniversary to Ongoing Anti-Imperialist Struggle

Kim Jong Un emphasizes dismantling imperialism and strengthening ties with Russia during the 80th anniversary of Korea's liberation.

South Korea Reports No Radiation Risk From Suspected North Korean Uranium Waste for Second Month

South Korean monitoring confirms no abnormalities in water quality near North Korea's uranium plant, alleviating contamination concerns.

Tag: clinical trials

North KoreaKoreaKimMilitarySouth KoreaAIrelationsmarketInternational

SleepQ vs. Traditional Medications: Which is the Future of Insomnia Treatment?

Welt aims to complete clinical trials for its SleepQ insomnia device by year-end, targeting listing on Germany's DiGA reimbursement system.

HLB BioStep Signs Strategic MOU with CLIPS BnC… Toward Integrated Preclinical and Clinical Development

HLB BioStep and CLIPS BnC sign MOU to enhance collaboration between preclinical and clinical stages of drug development.

An AI Endoscope Built in Korea: Lighter Controls, Custom Alerts, and a Push Into the U.S. Next

Meditech is revolutionizing endoscopic surgery with AI-driven devices, enhancing diagnosis and treatment while securing significant investments.

ABL209 Receives FDA Approval: What This Dual Antibody ADC Means for Cancer Treatment

ABL Bio receives FDA approval for ABL209, a bispecific antibody-drug conjugate, advancing ADC development for solid tumors.

How JNPMEDI Plans to Achieve 250% Revenue Growth in 2026: A Guide for Pharma Innovators

JNPMEDI aims to enhance its global role in drug and medical device development, achieving significant growth and expanding partnerships.

Unlocking Weight Loss: How Celltrion’s New CT-G32 and Oral Multi-Action Drug Will Change the Game

Celltrion aims to lead the obesity treatment market with innovative drugs, enhancing efficacy and patient convenience through dual approaches.

South Korean Biotech Seeks Breakthrough in $Trillion-Scale Alzheimer’s Market

AriBio's AR1001 is a promising oral Alzheimer's drug aiming for global blockbuster status by 2027, focusing on convenience and safety.

A New Hair-Growth Pathway?: JW0061 Targets GFRA1 After 7.2x Organoid Results and a 39% Animal Boost

JW Pharmaceutical's hair loss treatment JW0061 gains FDA approval for clinical trials, promising innovative growth stimulation for men and women.

JW Pharmaceutical Advances Gout Treatment with Epaminurad

JW Pharmaceutical advances its gout treatment, Epaminurad, with global trials nearing completion and U.S. patent secured for market entry.

CT-P55: How Celltrion’s New Biosimilar Approval Will Transform Clinical Trials in Europe

Celltrion receives EMA approval to reduce patient enrollment for CT-P55 trial, aiming to cut costs and duration of clinical development.

Unlocking Weight Loss: Hanmi Pharmaceutical’s Innovative H.O.P Project and the Game-Changing Epaglenatide

Hanmi Pharmaceutical is innovating obesity treatment with efpeglenatide and HM15275, focusing on tailored solutions for Korean patients.

FDA Grants Breakthrough Therapy Designation to Hanmi’s Epheglucagon: What This Means for Rare Disease Treatment

Hanmi Pharmaceutical's efpegerglucagon receives FDA Breakthrough Therapy designation for treating rare Congenital Hyperinsulinism, with Phase 2 results due soon.

SJN314: The Promising New Immunotherapy for Chronic Inflammatory Diseases in Asia

Samjin Pharmaceutical submits phase 1 trial plan for SJN314, targeting immune diseases, aiming for global partnerships in early clinical phases.

Chinese Biotech’s Rise: What’s the Standard of Global Tech Trade?

Analysts at the JPMHC noted a shift in biotech, with firms resisting sales and China emerging as a tech transfer leader.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.